Soluble α-Klotho levels, glycemic control and renal function in US adults with type 2 diabetes

Stefano Ciardullo1,2 · Gianluca Perseghin1,2

Received: 25 August 2021 / Accepted: 6 February 2022 / Published online: 14 March 2022 © The Author(s) 2022, corrected publication 2022

Abstract

Aims Soluble Klotho (s-Klotho) is associated with chronic kidney disease (CKD) and aging, but little is known on its relationship with chronic micro- and macro-vascular complications of type 2 diabetes and glycemic control. Here, we evaluate the association between s-Klotho levels, glycemic control and renal function in patients with type 2 diabetes (T2D).

Methods This is a cross-sectional study including 2989 patients with T2D and available s-Klotho measurements from the 2007–2016 cycles of the National Health and Nutrition Examination Survey (mean ± SE, age: 60.0 ± 0.2 years, BMI 33.3 ± 0.2 kg/m², 46.7 ± 1.3% female). Determination of s-Klotho concentrations was performed with a sandwich ELISA test.

Results Patients with higher s-Klotho levels were younger, more frequently female and had a lower prevalence of CKD and higher HbA1c levels. In multivariable linear regression models adjusting for age, race-ethnicity and BMI, both estimated glomerular filtration rate (B = 2.21, 95% CI 1.41–3.01, p < 0.001) and hemoglobin A1c (B = 37.38, 95% CI 28.91–45.86, p < 0.001) were positively associated with s-Klotho, while no significant association was found with cardiovascular disease. Results were confirmed when analyses were performed in men and women separately. No significant differences were identified between patients with an albuminuric or non-albuminuric CKD phenotype.

Conclusions s-Klotho levels are dependent on kidney function and glycemic control in patients with T2D. Additional studies elucidating the mechanisms linking glycemic control and s-Klotho levels and exploring their predictive ability of clinically meaningful outcomes in patients with diabetes are needed.

Keywords Klotho · CKD · Diabetes · HbA1c

Introduction

α-Klotho (referred here as Klotho) was serendipitously discovered in 1997 as a gene linked to aging in mice, with reduced gene expression being linked to a shortened life span [1]. It was later discovered that the gene codes for a transmembrane protein functioning as the obligate co-receptor for fibroblast growth factor 23 (FGF-23), a phosphaturic hormone essential for maintaining mineral homeostasis by regulating phosphorus, parathyroid hormone and vitamin D concentrations [2, 3]. Its expression is the highest in the distal tubules of the kidneys [4] and because its ectodomain seems to be shed constitutively, circulating levels of Klotho (referred here as soluble Klotho, s-Klotho) are thought to be a surrogate marker of renal Klotho expression and probably of functional nephron number [5]. In agreement with this hypothesis, it has been shown that s-Klotho levels decrease proportionately with decreasing estimated glomerular filtration rate (eGFR) in both cross-sectional and longitudinal studies performed in patients with chronic kidney disease (CKD) [6–9].

Klotho deficiency has also been shown to be associated with endothelial dysfunction and vascular aging [10], with several reports highlighting lower circulating levels in patients with several chronic conditions including...
hypertension, cardiovascular disease (CVD) and Alzheimer disease [11].

Few studies to date investigated s-Klotho levels in patients with diabetes and little information is available on its association with chronic micro- and macro-vascular complications as well as with glycemic control [12, 13].

Since in the 2007–2016 cycles of the National Health and Nutrition Examination Survey (NHANES) serum s-Klotho was measured for the first time in a large, US nationally representative sample, data from the survey were used in the present study to identify determinants of its concentration in US adults with type 2 diabetes (T2D).

Materials and methods

This is an analysis of data obtained in the 2007–2008 to 2015–2016 cycles of NHANES, a series of cross-sectional surveys conducted in the United States by the National Center for Health Statistics of the Centers for Disease Control and Prevention. Participants are selected from the US non-institutionalized, civilian population of all ages using a stratified, multistage, clustered probability sampling design. In order to derive reliable estimates with sufficient statistical power, oversampling of non-Hispanic black, Hispanic and Asian persons, people with low income and older adults is performed. The survey consists of a structured interview conducted in the home, followed by a standardized health examination performed at a mobile examination center, which includes a physical examination as well as laboratory tests. Full methodology of data collection is available elsewhere [14]. Among persons selected for the NHANES from 2007 to 2016, the response rates ranged from 75 to 55%. The original survey was approved by the Centers for Disease Control and Prevention Research Ethics Review Board and written informed consent was obtained from all adult participants. The present analysis was deemed exempt by the Institutional Review Board at our institution, as the dataset used in the analysis was completely de-identified.

Laboratory tests and clinical data

Participants reported age, sex, race and ethnic group (non-Hispanic white, non-Hispanic black, Hispanic, or other), a previous diagnosis of diabetes (and age at diagnosis) as well as a previous history of CVD (defined as a composite of coronary artery disease and stroke/transient ischemic attacks). Body measurements including height (cm), weight (kg) and waist circumference (cm) were ascertained during the mobile examination center visit; we calculated body mass index (BMI) as weight in kilograms divided by the square of the height in meters. After the participant rested in a seated position for 5 min, blood pressure was measured three times on the same arm with a mercury sphygmomanometer by trained medical personnel. The average of the three measures was used as the representative value in this analysis. Hypertension was defined as a systolic blood pressure (SBP) value ≥ 140 mmHg and/or a diastolic blood pressure (DBP) value ≥ 90 mmHg or currently taking antihypertensive drugs [15]. Diabetes was defined in accordance with the American Diabetes Association criteria if any of the following conditions were met: 1) A self-reported diagnosis of diabetes. 2) Use of anti-diabetic drugs. 3) A Hemoglobin A1c (HbA1c) level ≥ 6.5% (48 mmol/mol). 4) A fasting plasma glucose ≥ 126 mg/dl. 5) A random plasma glucose ≥ 200 mg/dl [16]. We excluded patients with probable type 1 diabetes (defined as an age of onset < 30 years and currently taking insulin as the only anti-diabetic drug).

HbA1c was measured with the use of high-performance liquid chromatography methods. Laboratory methods used to measure glucose, creatinine, calcium, phosphorus, albumin and other metabolites are reported in detail elsewhere [17]. Estimated glomerular filtration rate (eGFR) was computed according to the Chronic Kidney Disease Epidemiology Collaboration (CKD-EPI) equation. Based on the measured urine albumin to creatinine ratio (UACR), participants were defined as having normo-albuminuria (UACR < 30 mg/g), micro-albuminuria (UACR between 30 and 300 mg/g) or macro-albuminuria (UACR ≥ 300 mg/dL).

All respondents were asked if they had taken any prescription medications in the past 30 days. If so, they were asked to show the interviewers the containers; when they were not available, participants reported the medication names. All drugs were converted into standard generic drug name, and we categorized them into specific classes of anti-diabetic drugs.

s-Klotho measurements

Determination of s-Klotho concentrations was performed on frozen samples stored at −80 °C that were received and tested during the period 2019–2020. Available pristine serum samples from 40–79 years old participants, who gave consent for their samples to be used in future research, were analyzed with a sandwich ELISA test (IBL-International, Japan) at the Northwest Lipid Metabolism and Diabetes Research Laboratories, University of Washington. All sample analyses were performed in duplicate, and the average of the two values was used to calculate the final value, according to the manufacturer’s protocol; the results were checked to meet the laboratory’s standardized criteria for acceptability. The assay is reported to have a sensitivity of 6 pg/ml [18]; it was used in several prior publications and showed reasonable correlation with more labor-intensive assay methods using synthetic antibodies and
immune-precipitation-immunoblots. Additional information is available at the NHANES website.

**Study sample**

A total of 16,862 participants aged 40–79 years attended a mobile examination center visit. We initially excluded individuals without diabetes or with probable type 1 diabetes (defined as a diagnosis at age < 30 years and the use of insulin as the only anti-diabetic therapy), leading to a population of 3659 patients with T2D. Among these, 670 did not have a s-Klotho measurement, leading to a final sample of 2989 patients with T2D and S-Klotho data (Supplementary Fig. 1).

**Statistical analysis**

All analyses were conducted using Stata version 16.0 (StataCorp, College Station, TX), accounting for the complex survey design of NHANES. We used appropriate weighting for each analysis, as suggested by the NCHS. Sample weights are used to account for oversampling of certain populations and survey nonresponse.

We first examined participants’ characteristics by median s-Klotho levels. These were summarized as numbers and weighted proportions for categorical variables and as weighted means ± Standard Error (SE) for continuous variables. For eGFR, we also reported the proportion of participants in each group below or above clinically relevant cut-points. Features were compared using linear regression for continuous variables and the design-adjusted Rao-Scott Chi-square test for categorical variables.

Multivariable linear regression analysis was performed in order to evaluate the effect of different variables on circulating s-Klotho levels. The contribution of glycemic control and CVD complications was evaluated after adjustment for age, sex and race ethnicity. Sensitivity analyses were performed by repeating the analysis in men and women separately. A two-tailed value of p < 0.05 was considered statistically significant.

**Results**

Clinical and biochemical features of the study population according to s-Klotho levels are shown in Table 1. Mean (SE) age was 60.0 (0.2) years, with 46.7% women. The median s-Klotho level was 805.4 pg/ml (25th–75th percentile = 646–1020 pg/ml). Mean eGFR was 83.6 ml/min/1.73m², with 16.4% of patients having an eGFR < 60 ml/min/1.73m² and 25.3% having an UACR > 30 mg/g.

Patients with s-Klotho levels below the median were significantly older (61.1 vs 58.9 years, p < 0.001) and less frequently female (44.1 vs 49.4%, p = 0.046), while no significant difference was found in BMI. Among laboratory parameters, HbA1c levels were significantly lower in patients with lower s-Klotho levels (7.1 vs 7.6%, p < 0.001), together with a lower eGFR (79.8 vs 87.6 ml/min/1.73m², p < 0.001), while a non-significant trend was identified in terms of UACR. No differences were identified in phosphorus and calcium concentrations.

Moreover, patients with reduced s-Klotho concentrations also displayed a higher prevalence of hypertension and CKD, while no statistically significant differences were identified in both CVD and micro- and macro-albuminuria. Finally, no significant differences were identified in glucose-lowering drugs, with the exception of insulin, which was more commonly used in patients with lower s-Klotho levels (21.0% vs 16.0%, p = 0.010). Nonetheless, mean s-klotho levels in patients treated with insulin did not significantly differ from those of patients treated with metformin or sulfonylureas (818.5 vs 824.4, p = 0.763).

**Impact of kidney function and glycemic control**

Figure 1 shows the relative impact of reduced eGFR and increased UACR on s-Klotho concentration. We did not identify a significant difference in s-Klotho levels in both patients with and without reduced eGFR when stratified according to UACR values. On the other hand, compared with patients without reduced eGFR, both patients with an albuminuric and non-albuminuric CKD phenotype showed significantly decreased s-Klotho levels (p < 0.001).

To evaluate the contribution of glycemic control on s-Klotho concentration, we stratified the study population based on eGFR and HbA1c levels using a cut-off point of 7.5% (which was chosen as close to the median HbA1c value in the entire sample). As shown in Fig. 2, patients with worse glycemic control displayed higher s-Klotho concentrations, particularly if renal function was preserved. Sensitivity analyses performed using different HbA1c cut-offs and performed separately in men and women confirmed these results (Supplementary Table 1).

The direct relationship between s-klotho and eGFR was also evident when NHANES participants without T2D (n = 10,776) were evaluated (Supplementary Table 2).

**Independent predictors of s-Klotho concentrations**

To evaluate the independent contribution of glycemic control, kidney function and cardiovascular disease on s-Klotho concentration, we performed a multivariable linear regression analysis adjusting for age, sex, BMI and race ethnicity. As shown in Table 2, a positive and statistically significant association was found between s-Klotho and increasing eGFR and HbA1c levels (p < 0.001 for both). A
non-significant trend was identified suggesting lower levels for women compared with men \( (p = 0.057) \). A negative relationship was also identified between s-klotho and UACR, particularly in women. On the other hand, we did not

### Table 1: Features of the study population according to s-Klotho levels

| Feature                        | Total (\( n=2989 \)) | Below median (\( n=1496 \)) | Above median (\( n=1493 \)) | \( p \) value |
|--------------------------------|-----------------------|------------------------------|-----------------------------|---------------|
| Age (years)                    | 60.0 ± 0.2            | 61.1 ± 0.4                   | 58.9 ± 0.3                  | < 0.001       |
| Age group (%)                  |                       |                              |                             |               |
| 40–49                          | 17.3 ± 1.0            | 14.6 ± 1.3                   | 20.1 ± 1.4                  | 0.001         |
| 50–59                          | 29.4 ± 1.2            | 27.8 ± 1.8                   | 31.1 ± 1.8                  |               |
| 60–69                          | 32.5 ± 1.4            | 32.9 ± 1.9                   | 31.9 ± 2.0                  |               |
| 70–79                          | 20.8 ± 0.7            | 24.6 ± 1.2                   | 16.8 ± 1.1                  |               |
| Female sex (%)                 | 46.7 ± 1.3            | 44.1 ± 1.8                   | 49.4 ± 1.8                  | 0.046         |
| Race-ethnicity (%)             |                       |                              |                             |               |
| Non-Hispanic white             | 60.2 ± 2.3            | 57.4 ± 2.8                   | 62.9 ± 2.4                  |               |
| Hispanic                       | 16.7 ± 1.7            | 19.1 ± 2.0                   | 14.6 ± 1.7                  |               |
| Non-Hispanic black             | 14.0 ± 1.2            | 14.6 ± 1.5                   | 13.5 ± 1.2                  |               |
| Other                          | 9.0 ± 0.9             | 9.0 ± 1.1                    | 9.1 ± 1.1                   |               |
| BMI (kg/m\(^2\))              | 33.3 ± 0.2            | 33.3 ± 0.2                   | 33.3 ± 0.4                  | 0.714         |
| T2D duration (years)           | 8.5 ± 0.2             | 9.4 ± 0.3                    | 7.6 ± 0.3                   | < 0.001       |
| Laboratory parameters          |                       |                              |                             |               |
| HbA1c (%)                      | 7.4 ± 0.0             | 7.1 ± 0.1                    | 7.6 ± 0.1                   | < 0.001       |
| eGFR (ml/min/1.73m\(^2\))     | 83.6 ± 0.5            | 79.8 ± 0.7                   | 87.6 ± 0.7                  | < 0.001       |
| UACR (mg/g)                    | 113.4 ± 13.2          | 145.8 ± 22.5                 | 79.5 ± 9.9                  | 0.051         |
| Calcium (mg/dL)                | 9.4 ± 0.0             | 9.5 ± 0.0                    | 9.4 ± 0.0                   | 0.626         |
| Phosphorus (mg/dL)             | 3.7 ± 0.0             | 3.7 ± 0.0                    | 3.8 ± 0.0                   | 0.731         |
| Comorbidities                  |                       |                              |                             |               |
| Hypertension (%)               | 71.3 ± 1.2            | 74.5 ± 1.6                   | 67.9 ± 1.7                  | 0.034         |
| eGFR category (%)              |                       |                              |                             | < 0.001       |
| > 60                           | 83.6 ± 0.7            | 78.0 ± 1.2                   | 89.6 ± 1.0                  |               |
| 45–60                          | 10.2 ± 0.8            | 13.3 ± 1.3                   | 7.0 ± 0.9                   |               |
| 30–45                          | 4.0 ± 0.5             | 5.4 ± 0.7                    | 2.5 ± 0.4                   |               |
| < 30                           | 2.1 ± 0.3             | 3.2 ± 0.6                    | 0.9 ± 0.3                   |               |
| Cardiovascular disease         | 21.5 ± 1.0            | 23.2 ± 1.6                   | 19.7 ± 1.5                  | 0.125         |
| UACR (%)                       |                       |                              |                             | 0.108         |
| < 30                           | 74.7 ± 1.1            | 73.3 ± 1.7                   | 76.1 ± 1.4                  |               |
| 30–300                         | 19.2 ± 1.1            | 19.5 ± 1.5                   | 18.9 ± 1.3                  |               |
| > 300                          | 6.1 ± 0.7             | 7.2 ± 1.0                    | 5.0 ± 0.7                   |               |
| Glucose-lowering drugs         |                       |                              |                             |               |
| Metformin (%)                  | 52.0 ± 1.1            | 54.2 ± 1.7                   | 49.6 ± 1.8                  | 0.091         |
| Insulin (%)                    | 18.6 ± 1.0            | 21.0 ± 1.5                   | 16.0 ± 1.3                  | 0.010         |
| Sulfonylureas (%)              | 26.8 ± 1.1            | 27.9 ± 1.6                   | 25.7 ± 1.4                  | 0.256         |
| GLP1-RA (%)                    | 2.9 ± 0.5             | 2.4 ± 0.6                    | 3.4 ± 0.6                   | 0.291         |
| SGLT2-i (%)                    | 0.5 ± 0.2             | 0.6 ± 0.4                    | 0.3 ± 0.1                   | 0.448         |
| DPP4-i (%)                     | 8.0 ± 0.7             | 8.4 ± 1.1                    | 7.6 ± 1.0                   | 0.620         |
| TZD (%)                        | 8.5 ± 0.7             | 8.9 ± 1.2                    | 8.1 ± 1.0                   | 0.651         |

Data are expressed as weighted proportions (± Standard Error (SE)) for categorical variables and as weighted means± SE for continuous variables. Linear regression and Rao-Scott Chi-square test were used to compare groups. The median s-Klotho level was 805.4 pg/ml.

*BMI* Body mass index, *UACR* Urinary albumin creatinine ratio, *HbA1c* Hemoglobin A1c, *eGFR* Estimated glomerular filtration rate.
identify any significant relationship between s-Klotho and age, BMI and CVD.

Discussion

This is to our knowledge the first study evaluating determinants of s-Klotho concentrations in a large, unselected sample of patients with T2D from the general population. Our main findings are that s-Klotho levels are significantly higher in patients with preserved kidney function and worse glycemic control. Both relationships were robust in both men and women and after adjustment for potential confounders.

Several smaller studies investigated the relationship between s-Klotho levels and eGFR, demonstrating lower circulating levels being associated with worsening kidney function, particularly in patients on hemodialysis. Our study expands on these results by focusing on the largest population to date of patients with T2D with and without CKD and by demonstrating that reduced eGFR, and not albuminuria is a significant determinant. This was evident by the lack of difference in s-Klotho concentrations between patients with albuminuric and non-albuminuric CKD phenotypes. While both phenotypes are associated with increased mortality rates in patients with T2D [19], we may speculate that s-Klotho concentrations might not capture glomerular disease leading to albumin excretion, but rather be a marker of the number of functional nephrons and therefore be more strictly related to eGFR. Additional studies are needed to evaluate whether low s-Klotho may be considered also a risk factor, and not only a marker, of renal impairment, as recently suggested by a longitudinal study performed on older adults [6].

The second association, related to higher s-Klotho levels being present in patients with worse glycemic control, independently of kidney function, is a novel finding. The association was robust in both men and women, across groups of eGFR and after adjustment for age, sex, race ethnicity and CVD. Since Klotho is reported as an anti-aging gene and T2D has been considered by some as a condition of accelerated senescence, one would expect lower levels in patients with worse diabetes control. This unexpected finding might be related to the effects of glycosuria increasing metabolic demands in the proximal and distal kidney tubules, which in turn might lead to increased klotho expression and/
Table 2  Multivariable linear regression model assessing the contribution of several predictors on s-Klotho levels in the studied population

| Variables          | Both sexes | Men     | p value | Women | p value |
|--------------------|------------|---------|---------|-------|---------|
|                    | B          | 95% CI  | p value | B     | 95% CI  | p value |
| Age (years)        | 0.075      | −1.684−1.835 | 0.932 | −0.032 | −2.305−2.241 | 0.978     | 0.213 | −2.583−3.009 | 0.880     |
| Race–ethnicity   | 6.532      | −7.260−20.324 | 0.549 | −2.455 | −22.323−17.323 | 0.806     | 13.179 | −5.538−31.896 | 0.165     |
| BMI (kg/m²)       | 0.197      | −2.109−2.503 | 0.866 | −2.988 | −5.902 to 0.075 | 0.045     | 2.175 | −1.040−5.390 | 0.182     |
| UACR (mg/g)       | −0.017     | −0.033−0.000 | 0.044 | −0.013 | −0.040−0.013 | 0.314     | 0.018 | −0.034 to 0.001 | 0.036     |
| eGFR (ml/min/1.73m²) | 2.211      | 1.405−3.017 | <0.001 | 2.459 | 1.356−3.562 | <0.001 | 2.140 | 1.069−3.210 | <0.001     |
| CVD                | −13.086    | −46.579−20.407 | 0.439 | 0.557 | −41.608−42.721 | 0.979     | −18.996 | 69.597−31.605 | 0.457     |
| HbA1c (%)         | 37.381     | 28.907−45.856 | <0.001 | 41.780 | 28.934−54.626 | <0.001 | 32.678 | 19.762−45.595 | <0.001     |

*BMI* Body mass index, *CVD* Cardiovascular disease, *eGFR* Estimated glomerular filtration rate, *HbA1c* Hemoglobin A1c, *UACR* Urine albumin to creatinine ratio, *CI* Confidence interval

or cleavage resulting in higher serum concentrations. It should be noted that a previous study showed that exposure to high glucose levels did not alter Klotho expression in human isolated tubular epithelial cells [12]. It is nonetheless possible that a different response might be elicited in the intact nephron, based on potential paracrine and endocrine regulators.

The lack of association between s-Klotho and CVD is in line with a previous study by Zhang et al. in patients with T2D [20]. The authors did not identify significant relationships between micro- and macro-vascular diabetes complications and s-Klotho concentrations, with the exception of diabetic nephropathy.

Our study has several strengths. It is the largest study to date performed in an unselected sample of US adults with T2D, including both sexes and patients of different ethnic background. The high number of patients included yielded high statistical power to perform subgroup and sensitivity analyses and evaluate the impact of several predictors in multivariable models. Being based on NHANES data, our results have a high degree of external validity as the purpose of the survey is to be representative of the overall US population. Finally, acquisition of clinical, laboratory and anthropometric data was standardized and homogenous.

The present study also has some limitations that need to be acknowledged. First, its cross-sectional design does not allow causal inference to be demonstrated. On this aspect, future longitudinal investigations might shed light on the potential ability of s-Klotho to predict clinically relevant outcomes in patients with T2D. In fact, given that s-Klotho levels have been shown to associate with several variables, it is difficult to confer a clear biological meaning to our observation.

Second, concern has been raised as to the accuracy of the ELISA kit commercially available for s-Klotho measurement [21, 22]. Although the assay used in the present study might be less specific compared with highly labor-intensive immunoprecipitant immune blot assay methods [23], our results confirm previous findings on the association between s-Klotho and CKD. Moreover, it could be hypothesized that inaccuracy in the assay might lead to bias results toward the null, rather than producing a positive finding. Third, assessment of kidney function was performed by the CKD-EPI equation and not by more accurate techniques such as creatinine clearance or the gold standard inulin clearance; nevertheless, equations based on serum creatinine are well-suited for large epidemiological studies. Fourth, as data for the current study were obtained before 2015, the proportion of patients treated with drugs now representing the worldwide first choice in treating T2D (i.e., glucagon-like peptide-1 receptor agonists and sodium-glucose co-transporter 2 inhibitors) is very limited. Given that these agents might impact s-klotho levels, results obtained in the current study might not be applied to patients treated with these novel agents.

Conclusions

In conclusion, in this large population-based cross-sectional study including 2989 patients with T2D, serum levels of s-Klotho are positively associated with eGFR and HbA1c levels. On the other hand, no significant role was identified for obesity and CVD. Additional studies elucidating the mechanisms explaining the effect of worse glycemic control on s-Klotho concentration and exploring its predictive ability of clinically meaningful events are needed.

Supplementary Information The online version contains supplementary material available at https://doi.org/10.1007/s00592-022-01865-4.

Author's contribution All authors listed on the manuscript meet the criteria for authorship stated in the Uniform Requirements for Manuscripts Submitted to Biomedical Journals.

Funding Open access funding provided by Università degli Studi di Milano - Bicocca within the CRUI-CARE Agreement.
Data availability  All data analyzed during this study are publicly available at the NHANES website.

Declarations

Conflict of interest  No potential conflicts of interest related to this article were reported.

Ethical approval  The original survey was approved by the NCHS Research Ethics Review Board and all adult participants provided written informed consent. The present analysis was deemed exempt by the Institutional Review Board at our institution, as the dataset used in the analysis was completely de-identified.

Consent to participate  Written informed consent was obtained from all adult participants.

Code availability  Code is available from the corresponding author upon reasonable request.

Open Access  This article is licensed under a Creative Commons Attribution 4.0 International License, which permits use, sharing, adaptation, distribution and reproduction in any medium or format, as long as you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons licence, and indicate if changes were made. The images or other third party material in this article are included in the article’s Creative Commons licence, unless indicated otherwise in a credit line to the material. If material is not included in the article’s Creative Commons licence and your intended use is not permitted by statutory regulation or exceeds the permitted use, you will need to obtain permission directly from the copyright holder. To view a copy of this licence, visit http://creativecommons.org/licenses/by/4.0/.

References

1. Kuro-o M, Matsumura Y, Aizawa H et al (1997) Mutation of the mouse klotho gene leads to a syndrome resembling ageing. Nature 390(6655):45–51
2. Kurosu H, Ogawa Y, Miyoshi M et al (2006) Regulation of fibroblast growth factor-23 signaling by klotho. J Biol Chem 281(10):6120–6123
3. Shimada T, Hasegawa H, Yamazaki Y et al (2004) FGF-23 is a potent regulator of vitamin D metabolism and phosphate homeostasis. J Bone Miner Res 19(3):429–435
4. Hu MC, Shi M, Zhang J et al (2016) Renal production, uptake, and handling of circulating αKlotho. J Am Soc Nephrol 27(1):79–90
5. Kuro-o M (2019) The Klotho proteins in health and disease. Nat Rev Nephrol 15(1):27–44
6. Drew DA, Katz R, Kritchevsky S et al (2017) Association between soluble Klotho and change in kidney function: the health aging and body composition study. J Am Soc Nephrol 28(6):1859–1866
7. Neyra JA, Hu MC, Moe OW (2021) Klotho in clinical nephrology: diagnostic and therapeutic implications. Clin J Am Soc Nephrol 16(1):162–176
8. Pavik I, Jaeger P, Ebner L et al (2013) Secreted Klotho and FGF23 in chronic kidney disease Stage 1 to 5: a sequence suggested from a cross-sectional study. Nephrol Dial Transplant 28(2):352–359
9. Kim HR, Nam BY, Kim DW et al (2013) Circulating α-klotho levels in CKD and relationship to progression. Am J Kidney Dis 61(6):899–909
10. Kitagawa M, Sugiyama H, Morinaga H et al (2013) A decreased level of serum soluble Klotho is an independent biomarker associated with arterial stiffness in patients with chronic kidney disease. PLoS One 8(2):e56695
11. Kanbay M, Demiray A, Afsar B et al (2021) Role of Klotho in the development of essential hypertension. Hypertension 120:16635
12. Van Ark J, Hammes H-P, Van Dijk MC et al (2013) Circulating alpha-klotho levels are not disturbed in patients with type 2 diabetes with and without macrovascular disease in the absence of nephropathy. Cardiovasc Diabetol 12(1):1–11
13. Lee EY, Kim SS, Lee J-S et al (2014) Soluble α-klotho as a novel biomarker in the early stage of nephropathy in patients with type 2 diabetes. PLoS One 9(8):e102984
14. Centers for disease control and prevention. 2017: National Health and Nutrition Examination Survey (NHANES). U.S. Department of health and human services. Available from https://www.cdc.gov/nchs/nhanes/continuousnhanes/default.aspx?BeginYear=2017. (2017). Accessed April 10 2020
15. Williams B, Mancia G, Spiering W et al (2018) 2018 ESC/ESH Guidelines for the management of arterial hypertension: The Task Force for the management of arterial hypertension of the European Society of Cardiology and the European Society of Hypertension. J Hypertens 36(10):1953–2041. https://doi.org/10.1097/ jhy.0000000000001940
16. American Diabetes Association. 2. Classification and diagnosis of diabetes: standards of medical care in diabetes—2020 (2020). Diabetes Care 43 (Supplement 1):S14-S31
17. Centers for disease control and prevention. 2017: National Health and Nutrition Examination Survey (NHANES). U.S. Department of health and human services. Available from https://www.cdc.gov/nchs/nhanes/2017-2018/manuals/2017_MEC_Laboratory_Procedures_Manual.pdf accessed 31 March 2020.
18. Yamazaki Y, Imura A, Urakawa I et al (2010) Establishment of sandwich ELISA for soluble alpha-Klotho measurement: Age-dependent change of soluble alpha-Klotho levels in healthy subjects. Biochem Biophys Res Commun 398(3):513–518
19. Penno G, Solini A, Orsi E et al (2018) Non-albuminuric renal impairment is a strong predictor of mortality in individuals with type 2 diabetes: the Renal Insufficiency And Cardiovascular Events (RIACE) Italian multicentre study. Diabetologia 61(11):2277–2289. https://doi.org/10.1007/s00125-018-4691-2
20. Zhang L, Liu T (2018) Clinical implication of alterations in serum Klotho levels in patients with type 2 diabetes mellitus and its associated complications. J Diabetes Complications 32(10):922–930
21. Pedersen LS, Pedersen SM, Bransen CL, Rasmussen LM (2013) Soluble serum Klotho levels in healthy subjects. Comparison of two different immunoassays. Clin Biochem 46(12):1079–1083
22. Heijboer AC, Blankenstein MA, Hoenderop J, de Borst MH, Vervloet MG (2013) Laboratory aspects of circulating α-Klotho. J Bone Miner Res 28(1):223–228
23. Barker SL, Pastor J, Carranza D et al (2015) The demonstration of circulating αKlotho deficiency in human chronic kidney disease with a novel synthetic antibody. Nephrol Dial Transplant 30(2):223–233

Publisher’s Note Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.